Multiple Sclerosis, Rituximab, Hypogammaglobulinemia and Risk of Infections
Dr. Shuvro Roy and Dr. Annette Langer-Gould discuss the effective dose of rituximab and other B-cell depleting therapies in patients with multiple sclerosis, as well as important comorbidities to…
Read the full articleYou might also wanna read
Antiviral drugs targeting Epstein-Barr virus could offer new treatment path for multiple sclerosis
Low levels of replicating Epstein-Barr viruses might be the main driver of the autoimmune condition multiple sclerosis. This may mean that t
newscientist.com·1d agoAntiviral drugs targeting Epstein-Barr virus could offer new treatment path for multiple sclerosis
Low levels of replicating Epstein-Barr viruses might be the main driver of the autoimmune condition multiple sclerosis. This may mean that t
newscientist.com·1d agoEfficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Conditions : Autoimmune Encephalitis (AE); Autoimmune Cerebellitis Interventions : Drug: Blinatumomab Sponsors : Beijing Tiantan Hospital No
Rituximab Noninferior to Ocrelizumab in Relapsing MS
Rituximab is noninferior to ocrelizumab in suppressing disease activity in newly diagnosed multiple sclerosis, with a similar incidence of a
Does Epstein-Barr virus lead to multiple sclerosis?
Interview with Corey McGraw, MD
STAT+: New study untangles how Epstein-Barr viral infection triggers immune response in multiple sclerosis
A new study claims to have uncovered how Epstein-Barr virus launches immune responses seen in people with multiple sclerosis.
Q&A 174: multiple sclerosis and psoriasis
I have seen a handful of patients who prioritise their treatment of psoriasis with one of the licensed biological therapies for psoriasis.
Comments
Sign in to join the conversation.
No comments yet. Be the first.